SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

September 12, 2013 08:49 ET

Implant Sciences Receives State Grant for Training Manufacturing Employees at Its New 58,000 Sq. Ft. Facility

ISO 9001 and ISO 14001 Training Program Supports Excellence in Manufacturing for Made-in-the-USA High-Tech Systems

WILMINGTON, MA--(Marketwired - Sep 12, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today the start of a new ISO 9001 and ISO 14001 training program. This project supports the Company's expanded world class manufacturing operations. The training program is funded by a Workforce Training Fund grant through the Commonwealth of Massachusetts, executive office of Labor and Workforce Development. The grant program is administered by the Commonwealth Corporation.

"One of the major drivers of our recent move into our new 58,000 square foot facility was to have the room to grow our manufacturing capability to meet anticipated demand. This will require training many new employees in the ISO 9001 and ISO 14001 practices demanded in our industry," commented Brenda Baron, Implant Sciences' Vice President of Manufacturing.

"We use contract manufacturing for the QS-H150, but build the QS-B220 product in our facility," added Glenn D. Bolduc, President and CEO of Implant Sciences. "Orders continue to come for our QS-B220 product, and we currently have shipments scheduled into next quarter. We are pleased to receive the state grant, which helps train our employees, while we increase U.S. manufacturing jobs."

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that we will be required to repay all of our indebtedness to our secured lender, DMRJ Group, by March 31, 2014; if we are unable to satisfy our obligations to DMRJ and to raise additional capital to fund operations, DMRJ may seize our assets and our business may fail; we continue to incur substantial operating losses and may never be profitable; our independent registered public accounting firm has expressed substantial doubt as to our ability to continue as a going concern; our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; the risk that liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; the risk that our business is subject to intense competition; the risks that our markets are subject to rapid technology change and that our success depends on our ability to develop and introduce new products; the risks that we may not be able to retain our management and key employees or to identify, hire and retain additional personnel as needed; the risks that we may not be able to enforce our patent and other intellectual property rights or operate without infringing on the proprietary rights of others: and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

For further information, you are encouraged to review Implant Sciences' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the period ended June 30, 2012. The Company assumes no obligation to update the information contained in this press release.

Contact Information

  • Contact:

    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact